List of Genetic Analysis/Screening Companies with Phase 2 Active Clinical Trial - 27

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

ARCEDI Biotech ApS is a Danish biotech company involved in developing technologies for rare cell detection, a widely sought after application in the prenatal as well as cancer diagnostics. ARCEDI Biotech has proprietary method to enrich fetal cells from circulating maternal blood with high efficiency. Once enriched, the fetal cells can be utilized for downstream analysis using technologies such as FISH, 'Next Generation Sequencing', etc.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. They are the developer of biomarker-driven anti-cancer targeted therapies and have raised a total funding of $8M over 1 round from 7 investors.

bio.logis is a digital genomics company starting as a spin-off from a genetic diagnostic laboratory setting. Our goal is to develop smart applications and functionalities to drive the implementation of genetic data into clinical decision making. For laboratories and hospitals, we provide highly innovative software solutions enabling automated interpretation, diagnostic reporting & delivery of genetic data. This supports patients and physicians at point of care in making informed decisions based on information derived from DNA. Our vision We want DNA owners to have easy and secure access to reliable health-related information based on their DNA. Our goal is to create a sustainable ecosystem, where all stakeholders contribute to and benefit from maximizing diagnostic quality, improving patient care and promoting research. Our background The bio.logis team consists of experienced human geneticists, scientists and IT experts. Building software solutions for complex medical tasks requires excellent software development expertise and a deep understanding of medical decision making processes. Our team has been formed with exactly this in mind: uniquely combining comprehensive genetic diagnostics knowledge and IT development expertise.

Carbiotix is an award-winning biotechnology company pioneering the onsite upcycling of plant-based side-streams. Carbiotix mission is to improve the health of people by increasing the consumption of prebiotics and other active ingredients from upcycled side-streams. Carbiotix offers one core service today called NutraCycle, an on-site upcycling and fortification service allowing food & beverage, ingredient, and feed producers to turn plant-based products into healthier, more profitable, and sustainable products.

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

CJ Bioscience Global No.1 Microbiome Company CJ Bioscience is pioneering development of next-generation biopharmaceuticals for microbiome health with its leading edge in the field of ‘Wellness'. We aim to provide healthcare solutions for unmet medical needs by examining the relationships between human microbiomes and various diseases. In addition, CJ Bioscience, which uses leading world-class bioinformatic analysis technology, will discover promising candidates that can be used in the treatment of incurable diseases, and accelerate the development of new drugs utilizing our ‘Ez-Mx™ Platform' to become the global No. 1 microbiome company. Microbiome We plan to enter clinical trials (Phase 1) of a new drug development pipeline for treatment of immuno-oncology, autoimmune, and CNS (Central Nervous System) diseases and to promote technology export through joint research with Big Pharma. Also, we are constructing a ‘Ez-Mx™ Platform' by expanding on cohort studies (comparative disease research) and securing global microbiome big data. The next generation of genomic analysis We plan to expand our business area from next generation sequencing (NGS)-based microbiome genomic analysis to microbial infection diagnosis. We will further upgrade our state-of-the-art NGS and bioinformatics (BI) total solution services. We are expanding the global business capabilities of EzBioCloud, a global standard bioinformatic analysis service made for researchers combining a curated microbiome database and artificial intelligence (AI) technology, and TrueBacID, the world's first genome-based infection diagnosis service. In addition, through the global launch of Gut Inside, an intestinal.

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.

EdiGene is a clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER-based in vivo RNA base editing, ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T.

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Founded in 2014, HaploX aims to integrate liquid biopsy technology, gene sequencing, artificial intelligence, big data, and other technologies to improve the management of cancer patients. HaploX's technologies include tools for capturing circulating tumor DNA; extracting and amplifying ultra-low concentrations of DNA from liquid samples; performing tagged sequencing; and managing and analyzing the resulting data. Presently, HaploX's polycentric global distribution include: Shenzhen R & D Headquarter, Third-party Medical Laboratory, GMP Factory, US R & D center and ShangRao International Precision Medical Health Industrial Park. HaploX obtained a certificate of participation from EMQN(The European Molecular Genetics Quality Network) in 2017 and achieved both satisfactory results in two external quality assessment schemes: Lung Cancer(NSCLC)2 and Oncogene panel testing. HaploX possesses the most advanced platforms in the world: Illumina's NextSeqs, HiSeq X Tens, NovaSeq 6000 series and digital PCR. HaploX's throughput is now the second in the world rankings. In December 28th, 2017, HaploX Biotechnology raised $32 million in series A+ round. At the same time, NIVIDA accepted HaploX as a member in Inception program(a program started by NIVIDA in order to support startups that are revolutionizing industries with advances in artificial Intelligence and data science). The firm will continue to develop its sequencing technology, which is capable of detecting circulating tumor DNA for personalized cancer therapy.

Liquid biopsies provide better therapy options for more patients. Hedera Dx is on a mission to provide the next billion people with access to modern cancer care. We specialize in clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. Our culture is based on thinking different, modern and human, fostering a dynamic and innovative work environment.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. The RightMed Test may help providers optimize medication selection for their patients by analyzing and reporting on 27 genes. OneOme is privately held, based in Minneapolis, MN. For more information, visit www.oneome.com and follow us here for updates.

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

Pathios Therapeutics is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65. The company is focused on the development of first-in-class therapies for cancer.

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.

We are excited to continue to support women's health under the Labcorp name. Follow us @Labcorp

SOPHiA GENETICS is a healthcare company that specializes in genomics analysis using artificial intelligence and data analysis.